Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-22
    E.g., 2018-09-22


51716 items
3:39 PM, Sep 19, 2018  |  BC Extra | Company News

Molecular Templates gains on deal with Takeda

Building on a previous discovery collaboration, Molecular Templates Inc. (NASDAQ:MTEM) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered Wednesday to develop CD38-targeting engineered toxin bodies (ETBs) to treat multiple myeloma. Molecular Templates will receive $30 million...
3:27 PM, Sep 19, 2018  |  BC Extra | Politics & Policy

China looks to hone essential drug system

China's State Council outlined requirements on which drugs should be given priority for inclusion on the country's essential drug list, and recommended the creation of a system to monitor for drug shortages. The news was...
3:20 PM, Sep 19, 2018  |  BC Extra | Politics & Policy

HHS requests applicants for innovation and investment summit

HHS is calling for applicants to participate in the newly created Deputy Secretary’s Innovation and Investment Summit (DSIIS), a year-long collaboration between the private healthcare sector and HHS to identify ways to accelerate investment in...
2:11 PM, Sep 19, 2018  |  BC Extra | Financial News

Hillhouse closes $10.6B fund

Hillhouse Capital said it closed its oversubscribed Hillhouse Fund IV with $10.6 billion. The fund will invest in healthcare, consumer technology and services with a focus on Asia. Hillhouse’s Josh Gartner told BioCentury the fund does...
11:42 AM, Sep 19, 2018  |  BC Extra | Preclinical News

Mayo Clinic team implicates senescent cells in neurodegenerative diseases

Clearing out senescent brain cells could prevent tau-mediated neurodegeneration and cognitive loss, although it's still too early to determine whether the approach can halt or reverse disease progression, according to a Nature letter from Mayo...
11:24 AM, Sep 19, 2018  |  BC Extra | Company News

FDA wants extra trial for Pharming's Ruconest as HAE prophylactic

Pharming Group N.V. (Euronext:PHARM) said FDA requested another clinical trial of Ruconest conestat alfa as a prophylactic for hereditary angioedema in a complete response letter for an sBLA in the indication. Pharming, which fell €0.20 (20%)...
11:17 AM, Sep 19, 2018  |  BC Extra | Financial News

Ahead of Phase III mucositis study, Galera raises $150M

Galera Therapeutics Inc. (Malvern, Pa.) raised a combined $150 million in a $70 million series C round and $80 million royalty deal led by new investor Clarus. The fund-raising comes ahead of Galera's planned Phase...
10:34 AM, Sep 19, 2018  |  BC Extra | Financial News

argenx, G1 price follow-ons, CRISPR proposes

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) and G1 Therapeutics Inc. (NASDAQ:GTHX) raised $300.6 million and $180 million, respectively, in follow-ons that priced after hours Tuesday. argenx sold 3.5 million ADSs at $86.50, an 8% discount to its NASDAQ...
3:35 PM, Sep 18, 2018  |  BC Extra | Company News

Ono, Fate in off-the-shelf CAR T deal

Fate Therapeutics Inc. (NASDAQ:FATE) added $1.13 (10%) to $12.20 on Tuesday after partnering with Ono Pharmaceutical Co. Ltd. (Tokyo:4528) to develop and commercialize two off-the-shelf CAR T cell programs for cancer. The partners said each...
3:24 PM, Sep 18, 2018  |  BC Extra | Clinical News

Sosei, Allergan to delay trials of dementia candidate

Sosei Group Corp. (Tokyo:4565) and partner Allergan plc (NYSE:AGN) have suspended clinical development of neurodegenerative candidate HTL0018318 to investigate a toxicity signal -- a rare tumor -- found in a non-human primate treated with the...